Compare Cenovus Energy Inc (CVE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Cenovus Energy Inc trades at $31.36 (market cap $57.90B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: Cenovus Energy Inc is far larger — about 5.7× State Street SPDR S&P Biotech ETF's market cap, and Cenovus Energy Inc pays a 1.97% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CVE | XBI | |
|---|---|---|
Market Cap | $57.90B | $10.11B |
Volume | 7,863,588 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $33.92 | $169.55 |
52-Week Low | $15.85 | $104.99 |
Typical Hold Time | 46 Days | 38 Days |
Enterprise Value | $63.84B | — |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.39, up 2.48% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with a P/E of 12.43, ROE of 20.96%, and consistent earnings beats in recent quarters. Recent analyst upgrades and positive media coverage highlight growing optimism around the company's growth prospects and attractive valuation metrics.
CVE presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors should monitor energy price volatility and execution risks. The company's improving cash flow outlook and shareholder returns through dividends provide additional support for long-term value creation.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
